Nothing said here yet.
to join the conversation.
VERAXA is implementing FDA-aligned New Approach Methodologies ("NAMs") across its preclinical research programs, aiming to improve the relevance of experimental findings to human biology while reducing animal testing. The strategy supports developme...
LOS ANGELES, CA - October 13, 2026 (NEWMEDIAWIRE) - VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, presented its first in vivo proof-of-concept data and additional in vitro findings validating its BiTAC-ADC tec...
In vivo data confirm activation of prodrug payload inside tumor cells following systemic administration of BiTAC-ADC molecules leading to potent anti-tumor activityZURICH, SWITZERLAND – October 13, 2026 -- VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA”), an…
LOS ANGELES, CA - October 7, 2026 (NEWMEDIAWIRE) - VERAXA Biotech (NASDAQ: VRXA), a developer of next-generation antibody-based cancer therapies, provided an update on its strategy to implement U.S. Food and Drug Administration "FDA"-aligned New Appr...
Investing.com -- Veraxa Biotech AG (NASDAQ:VRXA) shares rose 3.7% in premarket trading Wednesday following the company's announcement of a strategy to implement FDA-aligned New Approach Methodologies across its preclinical programs.
Consistent Use of New Approach Methodologies (NAMs) to Potentially Accelerate BiTAC® Oncology Pipeline and Significantly Reduce Animal Testing NeedsZURICH, SWITZERLAND, Oct.
LOS ANGELES, CA - September 24, 2026 (NEWMEDIAWIRE) - VERAXA Biotech (NASDAQ: VRXA) is shifting its focus to advancing its oncology pipeline and implementing industrial partnerships for its technology platforms and products following the completion o...
VERAXA is advancing an oncology pipeline centered on its proprietary BiTAC(R) platform, alongside additional antibody-drug conjugate and engineered-antibody technologies. The company entered the NASDAQ market in June 2026 following its completed bus...
VERAXA has appointed Raju Willener as Chief Financial Officer, effective immediately. Willener brings more than 30 years of international experience spanning investment banking, corporate finance, asset management and capital markets. His appointmen...
VERAXA is developing antibody-based cancer therapies aimed at improving the therapeutic window of existing treatment modalities. Its proprietary BiTAC platform uses two complementary molecules that are designed to activate cytotoxic activity only wh...
By Karen Roman Veraxa Biotech AG (Nasdaq: VRXA) said it appointed Raju Willener as Chief Financial Officer, having previously served as Director of Corporate Development at Exentis Group AG, before becoming its CFO in 2025. Mr.
LOS ANGELES, CA - September 8, 2026 (NEWMEDIAWIRE) - VERAXA Biotech (NASDAQ: VRXA), a developer of next-generation antibody-based cancer therapies, announced the appointment of Raju Willener as chief financial officer, effective immediately. Willener...